E

Look for what is missing

An early stage landscape to watch out for with key changes happening in 2024

February 1, 2024
E

Pointing the way in AML

It's time to start pointing the way for new directions in the Menin niche

January 30, 2024
E

Insights on an emerging competitor landscape

What's next beyond BTK inhibition in lymphomas and CLL?

November 21, 2023
E

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023
E

Targeted Therapy Trials: Why some drug developers keep missing the mark

Do we need to pay more attention to the underlying biology in aggressive lymphomas?

September 5, 2023
E

Standing out from the crowd in AML

Encouraging new developments in the CAR-NK niche

June 27, 2023
E

Next generation CAR-T cell therapies for the future

From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products

June 22, 2023
E

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022
E

The Forgotten Checkpoints

What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?

May 26, 2022
E

Making a difference in aggressive lymphomas

Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL

June 22, 2021
E

New developments in hematologic malignancies to make your head turn

A look at two under the radar early developments in lymphomas which might have a shot at approval

June 17, 2021
E

A look at 6 key developments in advanced hematologic malignancies

A look at 6 IO products in the Heme space and what to watch out for.

June 10, 2021
E

Pillars of future strategies in tackling aggressive lymphomas

Some intriguing new developments in DLBCL to watch out for

August 20, 2020